Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
244 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Esophageal Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Esophageal Cancer - Pipeline Review, H2 2014', provides an overview of the Esophageal Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Esophageal Cancer Overview 8 Therapeutics Development 9 Pipeline Products for Esophageal Cancer - Overview 9 Pipeline Products for Esophageal Cancer - Comparative Analysis 10 Esophageal Cancer - Therapeutics under Development by Companies 11 Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes 14 Esophageal Cancer - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Esophageal Cancer - Products under Development by Companies 18 Esophageal Cancer - Products under Investigation by Universities/Institutes 21 Esophageal Cancer - Companies Involved in Therapeutics Development 22 Advantagene, Inc. 22 Advaxis, Inc. 23 Amgen Inc. 24 ArQule, Inc. 25 Aslan Pharmaceuticals Pte. Ltd. 26 AstraZeneca PLC 27 AVEO Pharmaceuticals, Inc. 28 Boehringer Ingelheim GmbH 29 Bristol-Myers Squibb Company 30 Celgene Corporation 31 Cerulean Pharma, Inc. 32 Daiichi Sankyo Company, Limited 33 Genmab A/S 34 GlaxoSmithKline plc 35 Glycotope GmbH 36 Hutchison MediPharma Limited 37 ImmunoFrontier, Inc. 38 ImmunoGen, Inc. 39 Immunomedics, Inc. 40 Karyopharm Therapeutics, Inc. 41 Mebiopharm Co., Ltd. 42 Meiji Seika Pharma Co., Ltd. 43 Merrimack Pharmaceuticals, Inc. 44 Novartis AG 45 Omeros Corporation 46 Omnitura Therapeutics Inc. 47 Oncolys BioPharma Inc. 48 Ono Pharmaceutical Co., Ltd. 49 Patrys Limited 50 Pfizer Inc. 51 Precision Biologics, Inc. 52 Recepta Biopharma S.A. 53 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 54 Supratek Pharma Inc. 55 Synta Pharmaceuticals Corp. 56 Takara Bio Inc. 57 Transgene Biotek Limited 58 Esophageal Cancer - Therapeutics Assessment 59 Assessment by Monotherapy Products 59 Assessment by Target 60 Assessment by Mechanism of Action 63 Assessment by Route of Administration 66 Assessment by Molecule Type 68 Drug Profiles 70 1-BB1 - Drug Profile 70 ADXS-HER2 - Drug Profile 72 afatinib - Drug Profile 73 alpelisib - Drug Profile 77 AMG-337 - Drug Profile 79 binimetinib - Drug Profile 80 BMS-833923 - Drug Profile 84 Cell Therapy 1 for Oncology - Drug Profile 86 Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile 87 cetuximab biobetter - Drug Profile 88 CRLX-101 - Drug Profile 89 dacomitinib - Drug Profile 91 DKN-01 - Drug Profile 93 doxorubicin - Drug Profile 95 ficlatuzumab - Drug Profile 97 ganetespib - Drug Profile 100 gefitinib - Drug Profile 104 Gene Therapy for Esophageal Cancer - Drug Profile 109 Gene Therapy to Activate p53 for Oncology - Drug Profile 110 GSK-2256098 - Drug Profile 111 HMPL-813 - Drug Profile 113 HuMax-TF-ADC - Drug Profile 114 IMF-001 - Drug Profile 115 IMGN-289 - Drug Profile 116 IMMU-132 - Drug Profile 117 KML-001 - Drug Profile 118 LJM-716 - Drug Profile 120 MBP-426 - Drug Profile 122 MM-111 - Drug Profile 124 MMD-37K - Drug Profile 126 MVX-ONCO-1 - Drug Profile 127 NEO-201 - Drug Profile 128 nimotuzumab - Drug Profile 130 nivolumab (recombinant) - Drug Profile 133 OBP-301 - Drug Profile 138 OMN-54 - Drug Profile 140 Oncolytic Virus for Oncology - Drug Profile 142 paclitaxel albumin bound - Drug Profile 143 panitumumab - Drug Profile 147 PAT-LM1 - Drug Profile 150 patritumab - Drug Profile 151 rAAV-VICN003 - Drug Profile 153 RebmAb-400 - Drug Profile 154 rhLT28-171 - Drug Profile 155 selinexor - Drug Profile 156 Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Drug Profile 159 Small Molecule to Target LGR5 for Esophageal Adenocarcinoma - Drug Profile 160 Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer - Drug Profile 161 talaporfin sodium - Drug Profile 162 TBI-1201 - Drug Profile 165 TBL-0805E - Drug Profile 167 tivantinib - Drug Profile 168 Vaccine for Esophageal Cancer - Drug Profile 171 Vaccine for Oncology - Drug Profile 172 varlitinib - Drug Profile 173 Esophageal Cancer - Recent Pipeline Updates 175 Esophageal Cancer - Dormant Projects 230 Esophageal Cancer - Discontinued Products 231 Esophageal Cancer - Product Development Milestones 232 Featured News & Press Releases 232 Appendix 239 Methodology 239 Coverage 239 Secondary Research 239 Primary Research 239 Expert Panel Validation 239 Contact Us 240 Disclaimer 240
List of Tables Number of Products under Development for Esophageal Cancer, H2 2014 13 Number of Products under Development for Esophageal Cancer - Comparative Analysis, H2 2014 14 Number of Products under Development by Companies, H2 2014 16 Number of Products under Investigation by Universities/Institutes, H2 2014 18 Comparative Analysis by Late Stage Development, H2 2014 19 Comparative Analysis by Clinical Stage Development, H2 2014 20 Comparative Analysis by Early Stage Development, H2 2014 21 Products under Development by Companies, H2 2014 22 Products under Development by Companies, H2 2014 (Contd..1) 23 Products under Development by Companies, H2 2014 (Contd..2) 24 Products under Investigation by Universities/Institutes, H2 2014 25 Esophageal Cancer - Pipeline by Advantagene, Inc., H2 2014 26 Esophageal Cancer - Pipeline by Advaxis, Inc., H2 2014 27 Esophageal Cancer - Pipeline by Amgen Inc., H2 2014 28 Esophageal Cancer - Pipeline by ArQule, Inc., H2 2014 29 Esophageal Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2014 30 Esophageal Cancer - Pipeline by AstraZeneca PLC, H2 2014 31 Esophageal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2014 32 Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 33 Esophageal Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 34 Esophageal Cancer - Pipeline by Celgene Corporation, H2 2014 35 Esophageal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2014 36 Esophageal Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 37 Esophageal Cancer - Pipeline by Genmab A/S, H2 2014 38 Esophageal Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 39 Esophageal Cancer - Pipeline by Glycotope GmbH, H2 2014 40 Esophageal Cancer - Pipeline by Hutchison MediPharma Limited, H2 2014 41 Esophageal Cancer - Pipeline by ImmunoFrontier, Inc., H2 2014 42 Esophageal Cancer - Pipeline by ImmunoGen, Inc., H2 2014 43 Esophageal Cancer - Pipeline by Immunomedics, Inc., H2 2014 44 Esophageal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 45 Esophageal Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2014 46 Esophageal Cancer - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2014 47 Esophageal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 48 Esophageal Cancer - Pipeline by Novartis AG, H2 2014 49 Esophageal Cancer - Pipeline by Omeros Corporation, H2 2014 50 Esophageal Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2014 51 Esophageal Cancer - Pipeline by Oncolys BioPharma Inc., H2 2014 52 Esophageal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 53 Esophageal Cancer - Pipeline by Patrys Limited, H2 2014 54 Esophageal Cancer - Pipeline by Pfizer Inc., H2 2014 55 Esophageal Cancer - Pipeline by Precision Biologics, Inc., H2 2014 56 Esophageal Cancer - Pipeline by Recepta Biopharma S.A., H2 2014 57 Esophageal Cancer - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2014 58 Esophageal Cancer - Pipeline by Supratek Pharma Inc., H2 2014 59 Esophageal Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 60 Esophageal Cancer - Pipeline by Takara Bio Inc., H2 2014 61 Esophageal Cancer - Pipeline by Transgene Biotek Limited, H2 2014 62 Assessment by Monotherapy Products, H2 2014 63 Number of Products by Stage and Target, H2 2014 65 Number of Products by Stage and Mechanism of Action, H2 2014 68 Number of Products by Stage and Route of Administration, H2 2014 71 Number of Products by Stage and Molecule Type, H2 2014 73 Esophageal Cancer Therapeutics - Recent Pipeline Updates, H2 2014 179 Esophageal Cancer - Dormant Projects, H2 2014 234 Esophageal Cancer - Discontinued Products, H2 2014 235
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
